The addition of oral iron improves chemotherapy‐induced anemia in patients receiving erythropoiesis‐stimulating agents
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34142
Abstract: Although many studies have shown that supplementation with iron and erythropoiesis‐stimulating agents (ESA) is frequently used for managing chemotherapy‐induced anemia (CIA), optimal combination therapy using these agents together to ameliorate anemia is not well characterized.… read more here.
Keywords: induced anemia; oral iron; chemotherapy induced; erythropoiesis stimulating ... See more keywords
Direct healthcare costs of chronic kidney disease management in Italy: What cost‐savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis‐stimulating agents?
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacoepidemiology and Drug Safety"
DOI: 10.1002/pds.5152
Abstract: Erythropoiesis‐stimulating agents (ESAs), are used for treating chronic kidney disease (CKD)‐related anemia, contributing to CKD costs. The study was aimed at investigating direct healthcare costs of CKD patients treated with ESAs and the potential savings… read more here.
Keywords: use; chronic kidney; direct healthcare; erythropoiesis stimulating ... See more keywords
Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-019-01787-6
Abstract: Background A decreased response to erythropoiesis-stimulating agents (ESAs) leads to refractory anemia and worse prognosis in patients with chronic kidney disease. We examined the association between autoantibodies to the erythropoietin receptor (EPOR) and responsiveness to… read more here.
Keywords: erythropoiesis stimulating; stimulating agents; epor antibodies; anti epor ... See more keywords
Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-021-02071-2
Abstract: Recent studies have suggested that erythropoiesis-stimulating agents (ESAs) may accelerate not only angiogenesis but also vasculogenesis, beyond erythropoiesis. We conducted a 12-week prospective study in 51 dialysis patients; 13 were treated with recombinant human erythropoietin… read more here.
Keywords: erythropoiesis stimulating; stimulating agents; endothelial progenitor; dialysis patients ... See more keywords
Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients
Sign Up to like & getrecommendations! Published in 2017 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfw328
Abstract: Background In 2012, new clinical guidelines were introduced for use of erythropoiesis-stimulating agents (ESA) in chronic kidney disease (CKD) patients, recommending lower haemoglobin (Hb) target levels and thresholds for ESA initiation. These changes resulted in… read more here.
Keywords: initiation; erythropoiesis stimulating; stimulating agents; study ... See more keywords
The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.15450
Abstract: Erythropoiesis‐stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [DIPSS] intermediate‐2/high risk; 52·5% transfusion‐dependent). Anaemia response (AR) rate was 54% and 76% of patients responded… read more here.
Keywords: erythropoiesis stimulating; stimulating agents; myelofibrosis; anaemia ... See more keywords
Clinical effectiveness and safety of erythropoietin‐stimulating agents for the treatment of low‐ and intermediate‐1−risk myelodysplastic syndrome: a systematic literature review
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Haematology"
DOI: 10.1111/bjh.15707
Abstract: Many patients with lower‐risk myelodysplastic syndrome (MDS) experience anaemia, which has negative consequences. Erythropoiesis‐stimulating agents (ESAs) and their biosimilars are used to treat anaemia in MDS and, currently, epoetin alfa and darbepoetin alfa are commonly… read more here.
Keywords: risk; safety; stimulating agents; myelodysplastic syndrome ... See more keywords
Biosimilar erythropoiesis‐stimulating agents are an effective and safe option for the management of myelofibrosis‐related anemia
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13910
Abstract: Erythropoiesis‐stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B‐ESA), in myelofibrosis (MF) is not well established. read more here.
Keywords: biosimilar erythropoiesis; erythropoiesis stimulating; agents effective; myelofibrosis ... See more keywords
Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy
Sign Up to like & getrecommendations! Published in 2017 at "BMJ Open"
DOI: 10.1136/bmjopen-2016-011637
Abstract: Objectives To evaluate the benefit/risk profile of epoetin α biosimilar with the erythropoiesis-stimulating agents (ESAs) originators when administered to naïve patients from clinical practice. Design Population-based observational cohort study. Setting All residents in the Lazio… read more here.
Keywords: biosimilars originators; erythropoiesis stimulating; safety; stimulating agents ... See more keywords
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207231152746
Abstract: Platelets, derived from a certain subpopulation of megakaryocytes, are closely related to hemostasis, coagulation, metastasis, inflammation, and cancer progression. Thrombopoiesis is a dynamic process regulated by various signaling pathways in which thrombopoietin (THPO)–MPL is dominant.… read more here.
Keywords: treatment thrombocytopenia; thrombopoiesis stimulating; thrombopoiesis; stimulating agents ... See more keywords
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update.
Sign Up to like & getrecommendations! Published in 2019 at "Blood advances"
DOI: 10.1182/bloodadvances.2018030387
Abstract: PURPOSE To update the American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer. METHODS PubMed and the Cochrane Library were searched for randomized… read more here.
Keywords: hematology; erythropoiesis stimulating; stimulating agents; patients cancer ... See more keywords